Druhé nádory – příčiny, incidence a budoucnost

Díky stále se zlepšující diagnostice a pokrokům v léčbě se zvyšují počty přeživších onkologických pacientů. Na druhou stranu je nutné věnovat zvýšenou pozornost případným komplikacím léčby primárního nádoru, jako jsou např. druhé nádory, které v konečném důsledku představují hlavní příčinu úmrtí pacienta. Počet pacientů, kteří přežijí prvotní onkologickou diagnózu se každoročně zvyšuje asi o 2 %. Od 90. let 19. století, kdy byly vícenásobné primární malignity poprvé popsány, se staly třetí nejběžnější nádorovou diagnózou. Tento přehledový článek stručně shrnuje recentní informace o vícenásobných primárních novotvarech, jejich definici, etiologii, souvislosti s léčbou primárního nádoru, genetických dispozicích, vlivu faktorů životního prostředí i nových přístupech vhodných k jejich identifikaci.

Klíčová slova:
novotvary vícečetné primární – s léčbou spojené nádory – SEER program

Tato práce byla podpořena Evropským fondem pro regionální rozvoj a státním rozpočtem České republiky RECAMO CZ.1.05/2.1.00/03.0101, GA ČR P206/12/G151, IGA NT13794-4/2012 a prostředky institucionální podpory výzkumné organizace MOÚ poskytnuté MZ ČR – DRO (MOÚ, 00209805).

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Obdrženo:
2. 7. 2013

Přijato:
18. 8. 2013

Autoři: L. Koubková; R. Hrstka; P. Dobes; B. Vojtesek; R. Vyzula
Působiště autorů: Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
Vyšlo v časopise: Klin Onkol 2014; 27(1): 11-17
Kategorie: Přehled

Souhrn

Obdrženo:
2. 7. 2013

Přijato:
18. 8. 2013

Zdroje

1. Berrington de Gonzalez A, Curtis RE, Kry SF et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011; 12(4): 353– 360. doi: 10.1016/ S1470– 2045(11)70061– 4.

2. Dusek L, Muzik J, Gelnarova E et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2010; 23(5): 311– 324.

3. Billroth T (ed.). Geral surgical pathology and therapeutics in 51 Vorlesungen: a textbook for students and physicians in fifty‑ one lectures. 14th ed. Berlin: G. Rerimer 1889.

4. Warren S, Gates O. Multiple primary malignant tumors – a survey of the literature and statistical study. Am J Cancer 1932; 16: 1358– 1414.

5. Luciani A, Ascione G, Marussi D et al. Clinical analysis of multiple primary malignancies in the elderly. Med Oncol 2009; 26(1): 27– 31. doi: 10.1007/ s12032– 008– 9075– x.

6. Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol 2003; 26(1): 79– 83.

7. Evans HS, Møller H, Robinson D et al. The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 2002; 50(5): 647– 652.

8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57– 70.

9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646– 674.

10. Roukos DH. Genome‑ wide association studies: how predictable is a person‘s cancer risk? Expert Rev Anticancer Ther 2009; 9(4): 389– 392. doi: 10.1586/ era.09.12.

11. Broeks A, Schmidt MK, Sherman ME et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011; 20(16): 3289– 3303. doi: 10.1093/ hmg/ ddr228.

12. Anand P, Kunnumakkara AB, Sundaram C et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 2008; 25(9): 2097– 2116. doi: 10.1007/ s11095– 008– 9661– 9.

13. Park S, Bae J, Nam BH et al. Aetiology of cancer in Asia. Asian Pac J Cancer Prev 2008; 9(3): 371– 380.

14. Curtis RE, Freedman DM, Ron E et al. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973– 2000. National Cancer Institute. In: Bethesda MD. NIH Publ 2006.

15. Geryk E, Dite P, Kozel J et al. Cancer multiplicities in the Czech population. Cas Lek Cesk 2010; 149(4): 178– 183.

16. Nielsen SF, Nordestgaard BG, Bojesen SE. Associations between first and second primary cancers: a population‑based study. CMAJ 2012; 184(1): E57– E69. doi: 10.1503/ cmaj.110167.

17. Travis LB, Rabkin CS, Brown LM et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98(1): 15– 25.

18. Marees T, Moll AC, Imhof SM et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow‑up. J Natl Cancer Inst 2008; 100(24): 1771– 1779.

19. Marees T, van Leeuwen FE, de Boer MR et al. Cancer mortality in long‑term survivors of retinoblastoma. Eur J Cancer 2009; 45(18): 3245– 3253. doi: 10.1016/ j.ejca.2009.05.011.

20. Kleinerman RA, Tucker MA, Tarone RE et al. Risk of new cancers after radiotherapy in long‑term survivors of retinoblastoma: an extended follow‑up. J Clin Oncol 2005; 23(10): 2272– 2279.

21. Kleinerman RA, Yu CL, Little MP et al. Variation of second cancer risk by family history of retinoblastoma among long‑term survivors. J Clin Oncol 2012; 30(9): 950– 957. doi: 10.1200/ JCO.2011.37.0239.

22. Moll AC, Dommering CJ, Bosscha MI et al. Risk factors for the incidence of second cancers in survivors of retinoblastoma with a family history. J Clin Oncol 2012; 30(24): 3028. doi: 10.1200/ JCO.2012.43.7640.

23. Hemminki K, Li X, Dong C. Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10(7): 793– 798.

24. Noura S, Ohue M, Seki Y et al. Second primary cancer in patients with colorectal cancer after a curative resection. Dig Surg 2009; 26(5): 400– 405. doi: 10.1159/ 000229991.

25. Lee SH, Ahn BK, Baek SU. Multiple primary cancers in extracolonic sites with colorectal cancer. Int J Colorectal Dis 2009; 24(3): 301– 304. doi: 10.1007/ s00384– 008– 0583– 0.

26. Evans HS, Lewis CM, Robinson D et al. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 2001; 84(3): 435– 440.

27. Kmet LM, Cook LS, Weiss NS et al. Risk factors for colorectal cancer following breast cancer. Breast Cancer Res Treat 2003; 79(2): 143– 147.

28. Khalil S, Ceccarelli F. Colorectal cancer after breast cancer: magnitude of risk in clinical practice and in the literature. Tumori 2009; 95(1): 28– 31.

29. Mellemkjaer L, Friis S, Olsen JH et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006; 118(9): 2285– 2292.

30. Soerjomataram I, Louwman WJ, de Vries E et al. Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972– 2001. Breast Cancer Res Treat 2005; 93(1): 91– 95.

31. Zhang W, Becciolini A, Biggeri A et al. Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy. Breast Cancer Res 2011; 13(2): R38. doi: 10.1186/ bcr2860.

32. Brown LM, Chen BE, Pfeiffer RM et al. Risk of second non‑hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 2007; 106(3): 439– 451.

33. Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003; 30(6): 740– 748.

34. Chander R, Kapoor NK, Dhawan BN. Effect of picroliv on glutathione metabolism in liver and brain of Mastomys natalensis infected with Plasmodium berghei. Indian J Exp Biol 1992; 30(8): 711– 714.

35. Zablotska LB, Neugut AI. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 2003; 97(6): 1404– 1411.

36. Franklin J, Pluetschow A, Paus M et al. Second malignancy risk associated with treatment of Hodgkin‘s lymphoma: meta‑analysis of the randomised trials. Ann Oncol 2006; 17(12): 1749– 1760.

37. Thomas A, Mailankody S, Korde N et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012; 119(12): 2731– 2737. doi: 10.1182/ blood‑ 2011– 12– 381426.

38. Ng AK, Kenney LB, Gilbert ES et al. Secondary malignancies across the age spectrum. Semin Radiat Oncol 2010; 20(1): 67– 78. doi: 10.1016/ j.semradonc.2009.09.002.

39. Lei D, Sturgis EM, Liu Z et al. Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis 2010; 31(2): 222– 227. doi: 10.1093/ carcin/ bgp279.

40. Khuri FR, Lee JJ, Lippman SM et al. Randomized phase III trial of low‑dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006; 98(7): 441– 450.

41. Wu X, Spitz MR, Lee JJ et al. Novel susceptibility loci for second primary tumors/ recurrence in head and neck cancer patients: large‑ scale evaluation of genetic variants. Cancer Prev Res (Phila) 2009; 2(7): 617– 624. doi: 10.1158/ 1940– 6207.CAPR‑ 09– 0025.

42. Gutierrez VF, Marcos CA, Llorente JL et al. Genetic profile of second primary tumors and recurrences in head and neck squamous cell carcinomas. Head Neck 2012; 34(6): 830– 839. doi: 10.1002/ hed.21824.

43. Agrawal N, Frederick MJ, Pickering CR et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333(6046): 1154– 1157. doi: 10.1126/ science.1206923.

44. Li F, Sturgis EM, Chen X et al. Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer 2010; 116(10): 2350– 2359. doi: 10.1002/ cncr.25072.

45. Zhang X, Yang H, Lee JJ et al. MicroRNA‑related genetic variations as predictors for risk of second primary tumor and/ or recurrence in patients with early‑stage head and neck cancer. Carcinogenesis 2010; 31(12): 2118– 2123. doi: 10.1093/ carcin/ bgq177.

46. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006; 15(11): 2020– 2026.

47. Choi M, Craft B, Geraci SA. Surveillance and monitoring of adult cancer survivors. Am J Med 2011; 124(7): 598– 601. doi: 10.1016/ j.amjmed.2010.07.031.

48. Hayat MJ, Howlader N, Reichman ME et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12(1): 20– 37.

49. Bertucci F, Finetti P, Cervera N et al. Gene expression profiling and clinical outcome in breast cancer. OMICS 2006; 10(4): 429– 443.

50. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747– 752.

51. Pollack JR, Perou CM, Alizadeh AA et al. Genome‑ wide analysis of DNA copy‑ number changes using cDNA microarrays. Nat Genet 1999; 23(1): 41– 46.

52. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458(7239): 719– 724. doi: 10.1038/ nature07943.

53. Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463(7278): 191– 196. doi: 10.1038/ nature08658.

54. Thomas D. Gene- environment‑ wide association studies: emerging approaches. Nat Rev Genet 2010; 11(4): 259– 272. doi: 10.1038/ nrg2764.

55. Best T, Li D, Skol AD et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy‑induced second malignancies after Hodgkin‘s lymphoma. Nat Med 2011; 17(8): 941– 943. doi: 10.1038/ nm.2407.

56. Beroukhim R, Mermel CH, Porter D et al. The landscape of somatic copy‑ number alteration across human cancers. Nature 2010; 463(7283): 899– 905.